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In dementia, Alzheimer’s disease (AD) is the most common 
type, characterized by the deposits of neurofibrillary tangles and 
senile plaques with concomitant deterioration in spatial memory 
and other cognitive functions. Till date, although no cure is 
available for AD, a few treatment options offer help in reducing the 
symptoms. In the present study, the sequence 111-137 in the distal 
N-terminal charge transition region of tau, harbouring the 
pathologically relevant phospho-serine (pSer 113) and phospho-
threonine (pThr 123) (111TPpSLEDEAAGHVpTQARMVSKSKD 
GTGS137) was selected as a potential immunotherapeutic peptide. 
Polyclonal anti-peptide antibodies raised in rabbits effectively 
dissociated the oligomers/aggregates of recombinant human tau in 
vitro. Administration of affinity purified anti-peptide antibodies to 
the okadaic acid induced tauopathy model rats resulted in a 
significant progress in spatial memory functions in Barnes maze 
task with concomitant reduction in p-tau levels in the hippocampal 
homogenates. Thus, targeting the phospho-residue sequence 111-137 
in tau may be therapeutically relevant for AD and other related 
tauopathies. These antibodies may also have a clinical value in 
terms of immunosassay development for quantitation of pathology 
associated pSer113 and pThr 123 in AD samples.  
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Alzheimer’s disease (AD), the most common form of 
dementia, is characterized by gradual deterioration of 
cognitive functions due to diminished synaptic 
functions and loss of synapses with accumulation of 
insoluble amyloid ß (Aß) aggregates1 and hyperpho-
sphorylated tau in the form of neurofibrillary tangles 
(NFT)2 in the hippocampus and neocortex of the 
affected brain. Apart from AD, NFT are also seen in 
several other neurodegenerative disorders collectively 
referred to as tauopathies. No effective treatment is yet 
available for AD and related tauopathies. Till date, the 
available treatments include cholinesterase inhibitors 
and NMDA receptor blockers, which provide 
symptomatic relief. In this context, Aß based 
immunotherapy as a disease-modifying approach for 
AD is being extensively pursued, albeit with limited 
success3. This is partly because some of the approaches 
which have targeted the most toxic oligomeric/fibrillar 
species resulted in affecting the relevant physiological 
forms and, thus, caused toxicity4. This has necessitated 
the need for alternative targets of AD research. In this 
regard, since NFT pathology correlates better with the 
degree of dementia than Aß plaques5, targeting tau 
pathology might be more effective than Aβ-directed 
therapy for AD. In fact, therapeutic approaches that 
influence tau hyperphosphorylation, aggregation or 
propagation are being actively pursued6-9. A few mAbs 
recognising the epitopes on the N-terminus of tau 
protein10 and/or all six tau isoforms and active 
immunization with tau are being tested in clinical 
trials11,12. 
 
Earlier, we demonstrated that passive immunization 
of okadaic acid (OA) induced AD model rats with 
antibodies to the phospho-peptide sequence in the N-
terminal region (residues 50-71) containing the 
pathologically relevant phospho-amino acids (serine 
68, threonine 69 and threonine 71) significantly 
improved the performance of these rats in terms of 
reduction in latency with reduced number of errors in 
Barnes maze task, with a reduction in phospho-tau  
(p-tau) levels in these experimental model rats13. In the 
present study, we focussed on less explored region in 
the distal N-terminus of tau spanning the residues 111-
137 for the following reasons: (i) the chosen sequence 
possesses two distinct clusters of negatively charged 
residues followed by positively charged residues14;  
(ii) harbours Ser-113 and Thr-123 implicated to be 
phosphorylated in AD15; (iii) high predictive score for 
B-, T- and MHC-II epitopes within the sequence16. 
 
Material and Methods 
 
Animals 
Okadaic induced tauopathy model rats, earlier 
developed and characterized from this laboratory13 
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were made available for this study. This study has been 
approved by the Institutional Animal Ethics 
Committee (IAEC number: AEC/ 51/ 319/ N.C.). 
 
Materials 
The 27-amino acid long phospho-peptide of tau 
(111TPpSLEDEAAGHVpTQARMVSKSKDGTGS137) 
custom synthesized using Fmoc chemistry was purchased 
from Genpro Biotech Pvt Ltd (Gautam Budh Nagar, 
India). Purity (>90%) of the synthetic peptide was 
ascertained by HPLC analysis. Polyclonal anti-
phospho-peptide antibodies were raised in rabbits 
following the immunization protocol described 
earlier13. Recognition of the full length tau by these 
peptide antibodies was ascertained by ELISA. Affinity 
purification and preparation of Fab fragments of these 
antibodies were done following the procedures 
described earlier13. ELISA kits for quantitation of total 
tau (t-tau) (# MBS009429) and phospho tau (p-tau)  
(# MBS1600387) in rat hippocampal homogenates 
were obtained from My Bio Source (USA). 
Recombinantly expressed full length human tau used 
for aggregation studies13 was available in the 
laboratory. All other reagents used were purchased 
from Sigma Aldrich (Bangalore, India).  
 
Tau oligomer dissociation studies 
Aggregates of tau were prepared using the 
recombinant tau expressed and purified in our 
laboratory13 and their formation was confirmed by 
thioflavin S binding. An aliquot of the tau aggregate 
(0.3 mg/mL) was incubated with Fab fragments of the 
anti–phospho-peptide antibodies or pre-immune IgG 
(1.0 mg/mL) for 24 h with agitation at 37C and 
analyzed by 10% SDS-PAGE.  
 
Studies with experimental rats 
The passive immunization studies were followed 
according to the earlier described procedures13. Briefly, 
6-month-old female rats were first treated with a single 
dose of okadaic acid (OA) (500 ng/kg body w.) through 
intranasal route followed by 6 doses of affinity purified 
anti-phospho-peptide IgG (1.0 mg/ animal/i.p.) on 
alternate days, starting from second day till day 12 after 
OA administration. While the antibody treatment was 
in progress, the animals were subjected to behavioural 
assessment by Barnes maze as described earlier17. 
Briefly, the acquisition phase included a total of 15 
trials (3 trials/day), starting from day 6 till day 10 of 
the experimental procedure. The duration of each trial 
was restricted to a maximum of 2 min. In case the rat 
did not find the escape box within 2 min, it was gently 
guided to it. Latency (time taken by the rat to find the 
escape box) and errors (nose pokes into wrong holes) 
were recorded. After a gap of 5 days, on day 15, three 
trials were conducted and the retention was evaluated. 
The mean values of the three trials were calculated and 
the data presented. 
By using commercially available quantitative 
sandwich ELISA, total tau (t-tau) and phospho tau (p-tau) 
levels in the hippocampal homogenate were measured. 
The rat tau protein ELISA kit used in the present study 
was specific to rat species with assay sensitivity of  
2 pg/mL and detection range of 15.6-500 pg/mL. The 
rat phospho tau protein ELISA kit was specific to rat 
species with assay sensitivity of 0.56 pg/mL and 
detection range of 1-400 pg/mL.  
 
Statistical analysis 
The data were expressed as mean ± S.E.M. and 
differences between groups were analyzed by 
ANOVA, followed by Tukey’s multiple comparisons 
using GraphPad Version 3 (Prizm; GraphPad Software 
Inc, San Diego, California, USA). P <0.05 was 
considered statistically significant. 
 
Results and Discussion 
 
Tau, a heat stable protein is highly enriched in 
neuronal cells and plays an important physiological 
role in several cellular functions including the 
microtubule stabilization, axonal transport, nuclear 
functions, synaptic function and neuronal signalling 
pathways. In the CNS, tau can exist as six isoforms 
arising from alternative mRNA splicing, ranging in 
length between 351 and 441 amino acids. Tau 
undergoes several post-translational modifications 
including phosphorylation, glycosylation, methylation, 
acetylation, prolyl-isomerization, nitration, 
sumoylation and ubiquitylation during both the 
physiological and pathological conditions18. Among 
them, phosphorylation is the most studied phenomenon 
of tau19. In AD, hyperphosphorylation of tau results in 
destabilization and dissociation from microtubules, 
and accumulation as neurofibrillary tangles. Since 
NFTs and synaptic loss strongly correlate with 
cognitive impairment in AD patients, attention is being 
focussed on targeting the phosphorylated tau for 
immunomodulation in AD. Till date, although the Tau 
based immunotherapeutic approaches have focussed 
on all parts of the tau molecule, particularly those 
antibodies targeted against the N-terminus, 
microtubule binding region and the C-terminus are 
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being progressed into clinical trials (URL: 
https://clinicaltrials.gov).  
The structure-function relationship studies of tau 
revealed that the microtubule binding region is located 
in the C-terminal half of the protein20. The N-terminal 
portion extends from the microtubule region and 
interacts with cytoskeletal elements and the plasma 
membrane21. Oligomerization of the charge transition 
region (106-144 amino acids) within the N-terminal 
region of tau has been demonstrated earlier by ion 
mobility-coupled mass spectrometry, which has 
implications for normal and pathological tau action14.  
 
Selection of the epitope peptide 
The N-terminal region (residues 106-144) is 
involved in tau-dimer assisted microtubule growth for 
normal tau action14. N-terminal tau fragments 
accumulate in tauopathy conditions, and are the 
candidates for trans-synaptic pathological tau transfer 
in spreading the neurodegeneration. Herein, we 
scanned this sequence using the online resource (URL: 
www.iedb.org) for immunologically relevant phospho-
peptide epitope, to select for immunoneutralization 
studies in the experimental AD model rats. Our search 
resulted in selection of the 27-amino acid long peptide 
(111TPpSLEDEAAGHVpTQARMVSKSKDGTGS137) 
with a high predictive score for immunogenicity index 
within the peptide sequence. More importantly, the 
selected sequence has two pathologically associated 
phosphorylation sites at 113 (Serine) and 123 
(Threonine)15.  
 
Dissociation of Tau aggregates by polyclonal phospho-tau 
epitope peptide antibodies 
The influence of the anti-phospho-peptide 
antibodies in dissociating the aggregates of tau was 
assessed by SDS-PAGE analysis. The results presented 
in Fig. 1 suggest that the Fab fragments of these 
antibodies effectively dissociated the oligomers/ 
aggregates of tau in vitro, in particular, the higher order 
oligomers. The non-specific effect of dissociation by 
the antibodies was ruled out by conducting the 
experiment with Fab fragments of pre-immune IgG.  
 
Passive immunization studies  
In this study, okadaic acid (OA) induced tauopathy 
rats earlier characterized and available in the laboratory 
were chosen as the experimental models since it is well 
established that selective inhibition of PP2A by 
okadaic acid can induce an AD-like accumulation of 
hyperphosphorylated tau22 and cognitive deficiency in 
OA-treated rats23. Using these OA-rats, passive 
immunization studies were conducted with the 
phospho-peptide antibodies. It is evident from the 
results presented in Table 1 that anti-phospho-peptide 
antibody treated animals have shown marked reduction 
(up to 50%) in the number of errors and latency in 
finding the escape hole in comparison to pre-immune 
IgG treated rats. Antibody treatment significantly 
improved the spatial memory functions in OA rats. 
More importantly, passive immunization had 
dramatically decreased p-tau levels in the hippocampal 
homogenates (Table 1) without any significant change 
in the t-tau levels across the groups. Based on our 
results, it is hypothesized that, these antibodies may 
 
 
 
Fig. 1 — Representative SDS-PAGE (10%) images demonstrating 
the influence of the anti-phospho-peptide antibodies on 
dissociation of oligomers/aggregates of tau. [Shown are the 
mobility patterns of tau in the presence of Fab fragments of the 
anti-phospho-peptide antibodies (lane 1) or control (pre-immune) 
IgG (lane 2)] 
 
 
Table 1 — Performance by the experimental rats in Barnes maze task during the retention phase. The corresponding p-tau levels in the 
hippocampal homogenates are indicated 
Parameter Ctrl OA rats OA rats+Pre-immune IgG OA rats+Anti-phospho-peptide IgG 
Number of errors 1.3±0.4 4.9±0.8## 4.4±0.9 2.6±0.6* 
Latency (s) 15.4±3.7 61.4±6.5## 55.7±8.0 27.3±4.9* 
p-tau (pg/100 mg tissue) 50±24 85±29# 81±20 42±19* 
t-tau (pg/ 100 mg tissue) 252±34 258±49 231±44 264±37 
[n=6 in each sub-group. Data are presented as mean ± S.E.M. #P <0.05, ##P <0.001 compared to age matched controls. *P <0.05 compared 
to age matched OA treated rats. The data was analyzed by ANOVA followed by Tukey’s multiple comparisons test] 
 
INDIAN J EXP BIOL, MAY 2020 
 
 
358 
bind to the aggregates of tau, i.e. either extracellular or 
intracellular pathological species and by disposing 
them, these antibodies may halt disease progression. 
Alternatively, these antibodies may halt trans-cellular 
spread of pathological tau24 in the CNS. These 
antibodies may also have a clinical value in terms of 
immunosassay development for quantitation of 
pathology associated pSer113 and pThr 123 in AD 
samples. 
 
Conclusion 
Results obtained from the passive immunization 
studies conducted with antibodies to the phospho-
peptide (111-137) in OA induced AD rats are 
presented. The polyclonal antibodies raised against the 
sequence 111-137 in the distal N-terminal charge 
transition region of tau, harbouring the pathologically 
relevant phospho-serine (pSer 113) and phospho-
threonine (pThr 123) have effectively dissociated tau 
aggregates in vitro. Passive immunization with these 
anti-peptide antibodies have resulted in a significant 
progress in spatial memory functions in OA rats.  
A concomitant reduction in p-tau levels in the 
hippocampal homogenates of the anti-peptide antibody 
treated rats has also been recorded. Further studies are 
warranted to elucidate the mechanism of action of 
these phospho-peptide antibodies in improving the 
spatial memory functions and the possible therapeutic 
potential of the identified N-terminal phosphopeptide 
(residues 111-137) of Tau for AD/tauopathy vaccine 
development.  
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